Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In my conversations with DI, what I have deduced, and caution this is MY personal opinion on what I heard, is that they are already testing Flaskworks on their own; in a parallel stream to vaccine creation testing/training via standard clean room technology. I believe they are targeting end of Q1, early Q2 2022 completion for Flaskworks certification.
I'm right there with you and your minions Marzan. About 80% of my portfolio in NWBO at an average price of 1.14. Wish I bought when it was lower, but you live and learn. I'm comfortable with my position and don't lose an ounce of sleep because of the belief in the science as well.
I also understand and have made peace with the risk I am taking. Cheers
How about you do the work this time instead of planting your false claims and never providing evidence?
Go find us a 15-year long clinical trial conducted across at least 4 countries, that is challenging the soc for a rare & complex disease, that has had data lock at the height of COVID. Bonus points if you can find a trial that is also working alongside RAs to set a precedent in a more ethical way of how these Oncology trials are conducted in the future (ie. Historical control arm vs placebo).
Please share your findings when complete.
I believe Sawston news will spike the share price higher simply because of the compassionate use agreement in place and the 40-45 patient capacity per month. This will allow NWBO to begin capturing up to 100 million in revenue per year within that facility alone.
-I don't know if the demand of 45 patients per month is there at those numbers in the compassionate care use case.
-I also don't know however, how that revenue will translate to NWBOs overall valuation or market cap calculation. I'd allow the others who are much more well versed to comment on biotechnology valuation.
A+ post.
I should of clarified, what I meant was not the trial, but idh mutation status redefinition as non-GBM in terms of number of patients in the NWBO trial. But you answered my question in one of the previous posts of being roughly 12%.
thank you!
Flip, how do you think this will impact the results of DCvax? Has there been any indication yet?
Thanks for sharing this information.
Interesting article I found in my search for Checkpoint 548 trial results (though this paper is not discussing that specific trial):
Can I ask someone to post the link to the results of Checkpoint? I read the results press release and I didn't see any numbers of 32 months in the placebo group.
re: TLD release, I agree 100%.
-Positive take: The company is under extreme confidence to have not said a single word for this entire duration. The longer it goes on, the higher likelihood of positive results and potentially even more surprising information revealed.
-Negative take I've heard from the FUD audience: They are fighting with regulators based upon the weakness of the data or trial design, and numbers potentially aren't what we believe them to be.
This is where one who possesses critical thinking skills can apply deductive reasoning to see that the negative take has very limited merit, almost 0% based on all of the information & actions of NWBO.
MID - I agree with you. I do not think this is where they will launch TLD. My hope/belief is that it will be out prior, but even if not, I do not believe this is the appropriate forum to do so. I was simply sharing for user @aekusterer as he asked for the information.
Thanks man!
Yes - thanks Hoffman. @ATLnsider is who got me on this train of thought earlier this year with some great research he's done.
NWBO does have fast-track designation with other RA's, but for some reason their conversations with the FDA throughout the history of NWBO's operation have been kept close to the vest.
Here's their fast track designation in the UK: https://www.bioprocessonline.com/doc/nw-bio-s-cancer-vaccine-first-to-receive-pim-designation-in-u-k-s-early-access-scheme-0001
@hoffmann - see my post here - I believe NWBO is working towards either Orbis and/or RTOR. They have stated they are aware of both programs but have not divulged whether if/when/how they plan on using them.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166826751
I also created a graphical representation too:
(
)For all $NWBO investors that are worried with the price action, I hope that this helps provide some additional perspective: https://t.co/89UIDL0Bwq pic.twitter.com/aQOgea2Fpd
— KnowWhatYouHold (@KnowWhatYouHold) November 18, 2021
Yes! That's it. Thank you very much.
This was likely shared already in regards to the Sawston HTA license, but I found in my search for the insurance PDF regarding the report for the HTA license grant:
https://content.hta.gov.uk/sites/default/files/2021-10/2021-08-16%2022694%20Advent%20Bioservices%20Ltd%20Application%20Assessment.pdf
@MartyDg - LP is involved in many (& likely lucrative) business opportunities. 600K for her is very likely a drop in the bucket for what she pulls in through other avenues. The idea that she is delaying TLD to collect another paycheck is very silly. You're letting impatience get the best of you. I know how frustrating the wait and non-information is, but don't let yourself go down these illogical paths as easy it might seem.
Does anyone here recall this post regarding the Advent paperwork for DCvax? I'm trying to find it but IHUB is terrible at searching.
MI Dendream, there was a post probably summer 2020 where someone found the insurance claim form for Dcvax and it was handled by Advent. I wonder if anyone else remembers that post.
"Based on the companies’ cash positions and potential room to take on new debt, Porges said the 18 biopharma majors will have $1.72 trillion in M&A capacity. J&J topped the list with more than $200 billion in M&A firepower. Pfizer and Novartis followed with $175 billion and $154 billion, respectively. AbbVie, GSK, Bristol Myers Squibb and Merck will each boast more than $100 billion in firepower, the team figures."
"Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst says"
https://www.fiercepharma.com/pharma/m-a-large-biotech-pharma-companies-will-have-1-7t-firepower-for-dealmaking-2022
I appreciate this kind of dialogue very much.
I've touched on this very subject with DI, and my interpretation of the dialogue was that an expert on the SAB insisted at the 11th hour that they release TLD with publication as the implications could be potentially ground breaking.
Again, this is my interpretation of the dialogue and my opinion so take it for what it's worth.
Agreed. Over reaction by the market of course.
This was neither of the above. The market tanked at the end of today on renewed covid fears as they found an omicron case in the US. All other biotechnology companies were down exactly the same, 6-7%. Nothing NWBO specific.
I think it is clear what NWBO's game plan is. They are in the business of releasing facts, not speculation. When they have something factual, we will hear & know about it as evidenced by the most recent PRs.
The image didn't work in my previous post, so here's the link:
$NWBO - Marnix Bosch's presentation scheduled on 1/20/22 at the 3rd Annual Glioblastoma Summit pic.twitter.com/kNFetmGOxV
— KnowWhatYouHold (@KnowWhatYouHold) December 1, 2021
I wouldn't give AdamF that much credit. I think the stock traded down based on just price action/technicals.
Agreed. Somewhat of a non-answer but gives some general perspective.
In my conversations with DI on this subject, my interpretation of the dialogue has been that LP & company are not running the business with the intention of a buy out, but they cannot predict that it won't change post-TLD/approval and anything is open at that point.
Very interesting. Maybe a good potential fit with NWBO in the future - at least with Flaskworks.
Interesting. Thanks for the reminder Flip
Is streeterville capital = thermo?
I'm hoping to see a close above $1 too.
If this breaks through 1.03, we run back up to 1.10-1.20
Hah, Id like to think I was a better IT guy than that. I earned the nick name 'NickyFixIt' for actually getting to the root cause of issues. I used to hear it yelled from end to end on the floor lol.
Love that you use Bloomberg. I worked running IT support on a trading floor for about 8 years. Those screens bring back a lot of memories.
Great to hear how well your friend is doing 10Bag and I love seeing your name on the thread listing again. Missed ya. Stay well